Last reviewed · How we verify
High-dose esketamine infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
High-dose esketamine infusion (High-dose esketamine infusion) — Anqing Municipal Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| High-dose esketamine infusion TARGET | High-dose esketamine infusion | Anqing Municipal Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- High-dose esketamine infusion CI watch — RSS
- High-dose esketamine infusion CI watch — Atom
- High-dose esketamine infusion CI watch — JSON
- High-dose esketamine infusion alone — RSS
Cite this brief
Drug Landscape (2026). High-dose esketamine infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-esketamine-infusion. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab